Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). 1996

Z Estrov, and M Talpaz, and T F Zipf, and H M Kantarjian, and S Ku, and M V Ouspenskaia, and C Hirsch-Ginsberg, and Y Huh, and G Yee, and R Kurzrock
Department of Bioimmunotherapy, Division of Medicine, The University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA.

Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) is a malignant disorder characterized by a poor prognosis. In recent years hematopoietic growth factors have been used to recruit myeloid leukemia blasts into the proliferative phase of the cell cycle and as supportive agents, both with cytotoxic regimens and in the setting of bone marrow transplantation. This approach prompted us to investigate whether myeloid growth factors have a role in Ph1 positive ALL. To do this, we utilized two newly established Ph1-positive cell lines, Z-119 and Z-181. Both lines have L2 morphology, ultrastructural characteristics of lymphoblasts and typical B-lineage surface markers identical to those observed in the two Ph1-positive ALL patients from whom they were derived. In addition, a single rearranged immunoglobulin heavy-chain gene (JH) band was found in both cell lines by Southern blot analysis, confirming B-cell clonality. Cytogenetic analysis of the two lines revealed t(9;22). Polymerase chain reaction (PCR) amplified cDNA from both Z-119 and Z-181 cells revealed an e1--a2 BCR-ABL junction, and p190BCR-ABL protein was detected in them by the immune complex kinase assay. Both cell lines produce interleukin (IL)-1 beta, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage CSF (GM-CSF), but neither IL-1 beta, G-CSF, their corresponding antibodies and inhibitory molecules, nor GM-CSF, affected the cell lines' growth. However, GM-CSF neutralizing antibodies inhibited Z-181 but not Z-119 colony formation in a dose-dependent fashion by up to 77% and addition of GM-SCF reversed this inhibitory effect. Receptor studies with radiolabeled GM-CSF demonstrated specific binding to Z-181 but not to Z-119 cells, and Scatchard analysis revealed that Z-181 cells express high-affinity GM-CSF receptors. Furthermore, PCR analysis showed that Z-181 but not Z-119 bears the transcript for the GM-CSF receptor. Finally, studies using PH1-positive ALL patients' marrow cells revealed similar data. In 3 of 8 samples we detected significant concentrations of GM-CSF (7.5-13 pg/2 x 10(7) cells) and in 2 of 3 cases GM-CSF significantly stimulated Ph1-positive ALL colony proliferation. These data suggest that Ph1-positive ALL cells may produce GM-CSF, express GM-CSF receptors and thus show a proliferative response to this cytokine.

UI MeSH Term Description Entries
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D008297 Male Males
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010677 Philadelphia Chromosome An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE). Ph1 Chromosome,Ph 1 Chromosome,1 Chromosomes, Ph,Chromosome, Ph 1,Chromosome, Ph1,Chromosome, Philadelphia,Chromosomes, Ph 1,Chromosomes, Ph1,Ph 1 Chromosomes,Ph1 Chromosomes
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002892 Chromosomes, Human, Pair 22 A specific pair of GROUP G CHROMOSOMES of the human chromosome classification. Chromosome 22
D002999 Clone Cells A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed) Clones,Cell, Clone,Cells, Clone,Clone,Clone Cell
D005260 Female Females
D006133 Growth Substances Signal molecules that are involved in the control of cell growth and differentiation. Mitogens, Endogenous,Endogenous Mitogens

Related Publications

Z Estrov, and M Talpaz, and T F Zipf, and H M Kantarjian, and S Ku, and M V Ouspenskaia, and C Hirsch-Ginsberg, and Y Huh, and G Yee, and R Kurzrock
December 1998, Leukemia research,
Z Estrov, and M Talpaz, and T F Zipf, and H M Kantarjian, and S Ku, and M V Ouspenskaia, and C Hirsch-Ginsberg, and Y Huh, and G Yee, and R Kurzrock
January 1991, Blood,
Z Estrov, and M Talpaz, and T F Zipf, and H M Kantarjian, and S Ku, and M V Ouspenskaia, and C Hirsch-Ginsberg, and Y Huh, and G Yee, and R Kurzrock
September 2018, Hematology (Amsterdam, Netherlands),
Z Estrov, and M Talpaz, and T F Zipf, and H M Kantarjian, and S Ku, and M V Ouspenskaia, and C Hirsch-Ginsberg, and Y Huh, and G Yee, and R Kurzrock
September 1999, Human gene therapy,
Z Estrov, and M Talpaz, and T F Zipf, and H M Kantarjian, and S Ku, and M V Ouspenskaia, and C Hirsch-Ginsberg, and Y Huh, and G Yee, and R Kurzrock
September 1998, Human gene therapy,
Z Estrov, and M Talpaz, and T F Zipf, and H M Kantarjian, and S Ku, and M V Ouspenskaia, and C Hirsch-Ginsberg, and Y Huh, and G Yee, and R Kurzrock
March 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Z Estrov, and M Talpaz, and T F Zipf, and H M Kantarjian, and S Ku, and M V Ouspenskaia, and C Hirsch-Ginsberg, and Y Huh, and G Yee, and R Kurzrock
January 1996, Hematology (Amsterdam, Netherlands),
Z Estrov, and M Talpaz, and T F Zipf, and H M Kantarjian, and S Ku, and M V Ouspenskaia, and C Hirsch-Ginsberg, and Y Huh, and G Yee, and R Kurzrock
October 1997, The New England journal of medicine,
Z Estrov, and M Talpaz, and T F Zipf, and H M Kantarjian, and S Ku, and M V Ouspenskaia, and C Hirsch-Ginsberg, and Y Huh, and G Yee, and R Kurzrock
October 1997, The New England journal of medicine,
Z Estrov, and M Talpaz, and T F Zipf, and H M Kantarjian, and S Ku, and M V Ouspenskaia, and C Hirsch-Ginsberg, and Y Huh, and G Yee, and R Kurzrock
September 2018, Journal of global oncology,
Copied contents to your clipboard!